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a,b Saudi ArabiaBackground: Amphetamine-type stimulants (ATS) are the most commonly used illicit drugs in Saudi Arabia.
Frequency and outcome of ATS-related cardiovascular (CV) complications in the Saudi community have not been
previously studied.
Aim: We aimed to determine the incidence and the clinical outcomes of CV complications among individuals with
amphetamine-positive urine drug screening (APUDS) tests admitted to a tertiary care facility in Riyadh, Saudi Arabia.
Methods: Retrospective review of consecutive cases with APUDS and concurrently positive cardiac biomarkers
admitted to King Abdul-Aziz Medical City in Riyadh, Saudi Arabia, between January 2006 and December 2013. The
laboratory database was queried to identify patients with positive APUDS and abnormal cardiac biomarkers. Clinical
data were extracted from the electronic medical records.
Results: A total of 7450 urine drug screening tests were performed during the study period, out of which 720 (9.6%)
were positive for ATS (APUDS group). Forty-two cases in the APUDS group were documented to have CV complica-
tions. All cases were men with a median age of 39 years (range, 21–60 years). Acute coronary syndrome/myocardial
infarctionwas themost frequent clinical presentation (n = 31, 74%), predominantly in the formofST-elevationmyocar-
dial infarction. Other less frequent complications includedmyopericarditis, cardiomyopathy, and arrhythmia. Coron-
ary procedures were performed in 30 cases. Median hospital stay was 5 days (range, 1–28 days) and in-hospital
mortality was 7.2%.
Conclusion: APUDS is frequently encountered in young Saudimen presenting to the emergency department of our
institution. IndividualswithAPUDSare at increased risk of CV complications and in-hospitalmortality. Themost fre-
quent APUDS-related CV complication is acute coronary syndrome.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Abbreviations
ACS Acute Coronary Syndromes
APUDS Amphetamine Positive Urine Drug Screening
CKMB Creatinine Kinase MB
ICD International Classification of Diseases
MAP Methamphetamine
PCI Percutaneous Coronary Interventions
STEMI ST Elevation Myocardial Infarction
UDS Urine Drug Screening
WRS Water Restraint Stress
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Drug abuse is a major concern all over theworld. It is estimated that 246 million people
used illicit drugs in 2013 [1]. Like many other
wealthy countries, the Kingdom of Saudi Arabia
(SA) is frequently a target of drug smugglers. In
its 2014 annual report, the international narcotics
control board, clearly indicates that this is an
increasingly serious problem in SA and other Gulf
countries [2]. Long coastal areas of SA and sharing
borders with eight neighboring countries in addi-
tion to its sociodemographic characteristics and its
strategic geographical location are among the rea-
sons behind targeting SA as a destination country
of choice. Drug abuse is most frequently a prob-
lem of youth who constitutes the vast majority of
the Saudi population, where 27% of them are
younger than 25 years and those who are younger
than 55 years represent 73% [3]. Health-related
consequences of drug abuse are numerous and
well documented. A strategic plan and dedicated
resources are needed to increase public aware-
ness, implement prevention programs, and initi-
ate early treatment of the users. Published
studies about drug-related health issues in Arab
countries are limited and may underestimate the
magnitude of the problem [4,5]. There is a great
need for more research in this field at national
and regional levels.
Amphetamine-type stimulants (ATS) refers to a
group of psychostimulant drugs that are related to
the parent compound amphetamine and includes
amphetamine sulfate, amphetamine hydrochlo-
ride, methamphetamine, and phenethylamines
[6]. ATS group is currently the most commonly
abused substance in SA [7,8]. In recent years, the
frequency of amphetamine use among Saudi peo-
ple aged 640 years has markedly increased [8].
About 65% of patients in drug rehabilitation
programs in SA are reported as addicted to
‘‘Captagon’’ [9,10]. Captagon is originally a brand
name of fenethylline, a synthetic stimulant that
has been banned since 1986. Counterfeit versions
of Captagon contain amphetamine as the active
ingredient and represent the main source of ATS
in SA [10]. SA is the main country of destination
for Captagon tablets, which accounts for approxi-
mately 30% of all global amphetamine seizures
and for 80% of the total weight seized in the region
[10]. This fact reflects vigilance and collaborative
efforts of different government authorities against
drug smuggling; however, it may raise a concernthat large quantities of drugs may continue to
cross borders via unseized smuggling attempts.
ATS are known as potent sympathomimetic
amines that lead to several central nervous system
and cardiovascular (CV) system adverse effects
[11]. Acute central nervous system manifestations
of ATS abuse include euphoria, talkativeness, anx-
iety, restlessness, agitation, seizures, and coma.
Long-term abuse may lead to loss of weight, pul-
monary hypertension, cardiomyopathy, and para-
noid psychosis [12]. For social considerations and
privacy reasons, a history of drug abuse may be
denied by many users at the time of clinical pre-
sentation. ATS abuse is commonly suspected in
young individuals presenting with acute neu-
ropsychiatric manifestations or cardiac complica-
tions. Suspected cases are frequently tested for
presence of ATS or any of their metabolites in
the urine via urine drug screening (UDS).
Themedical literature is deficient in publications
onATS from theGulf andArab regions.Most of the
available literature is focused on the addiction and
psychiatric aspects. Very little scientific work has
been published on nonpsychiatric ATS-related
health problems, including CV complications [5].
The outcome of our study is expected to enhance
the medical staff and public awareness of potential
ATS-related CV complications.
This study aimed to determine the incidence
and outcomes of ATS-related CV complications
in patients admitted to King Abdul-Aziz Medical
City in Riyadh, Saudi Arabia over a period of
8 years. As a secondary objective, we aimed also
to evaluate the demographic profile of
amphetamine-positive UDS (APUDS) population
as well as the trends of UDS and its positivity rate
for ATS over the study period.Materials and methods
This hospital-based, retrospective, case-series,
study was approved by the King Abdullah Inter-
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entific Committee and was exempted from Institu-
tional Review Board (IRB) approval for obtaining
consent, as it did not involve patient contact or
human participant intervention. The study
included patients screened for ATS between Jan-
uary 2006 and December 2013. Potential candi-
dates were identified through searching the
biochemistry laboratory database for all individu-
als who underwent UDS during the study period.
UDS was performed using Enzyme Immunoassay
(Multigent, Architect c System; Abbott Laborato-
ries, Chicago, IL, USA) that detects amphetamine
and methamphetamine with a cutoff value of
1000 ng/mL for a positive test. Confirmatory test
using gas chromatography/mass spectrometry
(GC/MS) was not available for study candidates
as it is reserved, in our institution, for legal cir-
cumstances and not for a routine clinical use. Car-
diac biomarkers, i.e., troponin I (TnI) and
creatinine kinase MB isoenzyme (CK-MB; Archi-
tect STAT Troponin-I & CK-MB, Architect i Sys-
tem; Abbott Laboratories) were also collected
from the laboratory database for all individuals
who underwent UDS during the study period.
A comprehensive search for the discharge diag-
nosis of substance abuse, particularly for the ATS
abuse, according to the International Classifica-
tion of Diseases 9 and 10 coding systems was per-
formed through the Health InformationTable 1. Demographic profile and baseline characteristics of
amphetamine positive individuals who developed cardiovas-
cular complications (n = 42).
Parameter Median (range)
or n (%)
Age (y) 39 (21–60)
Sex (male) 42 (100)
Nationality (Saudi) 40 (95%)
Body mass index (kg/m2) 27 (18.5–40.8)
Heart rate (beats/min) 87 (36–130)
>100 9 (21)
<60 3 (7)
Respiratory rate (breaths/min) 20 (12–32)
Systolic blood pressure (mmHg) 126 (70–160)
>140 7 (16.6)
<100 6 (14)
Diastolic blood pressure (mmHg) 71 (41–114)
>90 3 (7)
<60 9 (21)
Oxygen saturation (%) 98 (90–100)
Smoking: current/ex-smoker 25 (60)
Nonsmoker 9 (20)
Unknown 8 (20)
Admit amphetamine-type
stimulants use
19 (45)
Multidrug use by urine test 17 (41)
Type II diabetes mellitus 11 (27.5)Management Department. A list of all individuals
with APUDS tests and their respective concurrent
cardiac biomarkers were electronically extracted
and carefully reviewed for potential study candi-
dates. Records of all individuals with APUDS
who were admitted to the hospital or were found
to have positive cardiac biomarkers (0.30 ng/mL
for TnI and 7.2 ng/mL for CK-MB according to
the manufacturer cutoff values and our laboratory
reference range) at the time of the index APUDS
test were carefully reviewed for potential cardiac
complications. Cardiac complications of interest
included acute coronary syndrome (ACS), acute
myopericarditis, cardiomyopathy, heart failure,
and arrhythmia. Relevant demographic and clini-
cal parameters were collected from multiple elec-
tronic hospital data management and archiving
systems. All data variables were managed and
analyzed using Microsoft Excel (Microsoft, Red-
mond, WA, USA) and IBM-SPSS software, version
20 (SPSS Inc.). Data security and confidentiality
were ensured at all times.Results
A total of 7450 UDS tests were performed during
the study period (88% men and 12% women), out
of which 720 (9.6%) were positive for ATS (Fig. 1).
Median age of the APUDS population was
29 years with male predominance (98%). Out of
the 720 APUDS, 209 (29%) and 134 (18.6%) under-
went concurrent TnI and CK-MB testing, respec-
tively. Values of 50 TnI and 60 CK-MB tests were
identified to satisfy the definition of acute myocar-
dial injury (>0.3 lg/L and >7.5 lg/L, respectively,
according to the manufacturer cutoff values and
our laboratory reference range). Forty-two indi-
viduals (5.8% of the total APUDS population andTotal UDS tests
N = 7450 (M:88%,F:12%)
Posive for ATS
N = 720 (9.7%)
Hospitalized > 24h
N = 241 (33.4%)
Cardiovascular 
complicaons 
N = 42 (17.4%)
Other complicaons
N = 201 (82.6%)
Not hospitalized
N = 479 (66.6%)
Negave for ATS
N = 6730 (91.3%)
Figure 1. Flow chart of study population identification, using urine
drug screening (UDS) for detection of amphetamine-type stimulants
(ATS). F = female; M = male.
17%
7% 2%
Cardiac complications
ACS Cardiomyopathy/HF Myopericarditis Arrhythmia
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identified to have documented CV complications
(CV group). These individual were all men and
their baseline characteristics are shown in Table 1
and Fig. 2.
The majority of cases (40 out of 42) were admit-
ted under cardiology services, while one patient
was admitted to the general Intensive Care Unit
and another one to a general medical ward. Most
cases were identified through the positive cardiac
biomarkers, while only three cases were coded for
substance abuse upon discharge. Details of the
cardiac investigations that were performed in the
42 patients are shown in Table 2. Diagnosis of
ACS/myocardial infarction (MI) was made in 31
cases (74%), while other complications were less
frequent (Fig. 3). Cardiac procedures and other
clinical outcomes are shown in (Table 3). Despite
the perceived trends of increasing UDS over the
study period, the ATS positivity rate has fallen
by 50% between 2006 and 2013 (Fig. 4). Individuals21-30 31-40 41-50 51-60
Frequency 7 15 13 7
0
2
4
6
8
10
12
14
16
Figure 2. Age distribution of the study population (total n = 42).
Table 2. Cardiac investigations among patients with cardio-
vascular complications (n = 42).
Parameter n (%) or
mean (SD)
ECG-ST segment: Elevation 20 (48)
Depression 6 (14)
Normal 16 (38)
Site of ST elevation: Anterior 12 (29)
Inferior 8 (19)
ECG-rhythm: Normal sinus 30 (72)
Sinus bradycardia 3 (7)
Sinus tachycardia 3 (7)
Atrial fibrillation 3 (7)
Others 3 (7)
Echo: LV wall: Hypertrophy 12 (28)
Thinning 2 (5)
Normal 28 (67)
Echo: ejection fraction (%) 39.6 (± 11)
P50 10 (23.8)
30–50 21 (50)
<30 11(26.2)
Troponin I (ng/mL) 36.8 (± 73)
ECG = electrocardiogram; LV = left ventricle; SD = standard deviation.older than 40 years were noted to have higher pro-
portion of diabetes mellitus and were more likely
to present with ACS, while admitting drug abuse
was more frequent in younger population
(Table 4).Discussion
Studies have shown that ATS increase heart
rate, blood pressure, and myocardial oxygen con-
sumption in a quantity similar to Dobutamine, 20–
40 lg/kg/min [13]. The natural history of ATS use74%
Figure 3. Distribution and frequency of cardiac complications in the
study group (n = 42). ACS = acute coronary syndrome; HF = heart
failure.
Table 3. In-hospital clinical outcomes of the study group
(n = 42).
Clinical outcome n (%) or
Median (range)
Cardiac procedures
Percutaneous coronary intervention 17 (40)
Diagnostic coronary angiogram only 10 (24)
Coronary angiogram followed by CABG 3 (7)
None 12 (29)
Median hospital stay (d) 5 (1–28)
In-hospital mortality 3 (7.2)
CABG = coronary artery bypass surgery.
Year
2006
Year
2007
Year
2008
Year
2009
Year
2010
Year
2011
Year
2012
Year
2013
Total UDS test 737 796 969 970 856 961 1057 1104
Posive result 102 96 73 90 98 96 89 76
Posivity rate 13.8% 12.1% 7.5% 9.3% 11.4% 10.0% 8.4% 6.9%
0
200
400
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1000
1200
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*
Figure 4. Annual trends of urine drug screening (UDS) and its
respective positivity rate for amphetamine-type stimulants between
2006 and 2013. *p < 0.001.
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Table 4. Comparison of clinical parameters in the study population according to their age category of >40 years or 640 years
(n = 42).
Clinical parameter 640 years (n = 22) >40 years (n = 20) p
Acute coronary syndrome 13 (59) 18 (90) 0.02
ST-elevation myocardial infarction 10 (46) 10 (50) 0.77
Mortality 1 (5) 2 (10) 0.49
Hospital stay 4.8 (3.0, 6.1) 7 (3.0, 10.5) 0.27a
Type II diabetes mellitus 1 (5) 10 (50) 0.001*
Hypertension 3 (14) 6 (30) 0.27
Admit drug abuse 14 (64) 5 (25) 0.01*
Multi drug use 8 (36) 9 (45) 0.57
Smoking 14 (64) 11 (55) 0.57
Troponin I level 7.5 (0.01, 26.75) 24.5 (6.0, 47.75) 0.35a
Hospital stay and troponin level are presented as median (interquartile range) and all other data are presented as n (%).
a Independent samples Mann–Whitney U test.
* p < 0.05.
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to cause pathology if taken for many years.
Long-term use of ATS has been linked to the
development of heart diseases and cerebral hem-
orrhage [14].
In animal models, combination of metham-
phetamine with water-restraint stress produced
a major rise in the leakage of proteins related to
myocardial damage and the levels of cytokines
interleukin-6, tumor necrosis factor-a, and
interleukin-10 due to cardiac myocytolysis [15].
ATS abuse can lead to cardiovascular toxicity that
eventually manifest as myocardial ischemia/
infarction, arrhythmia, or heart failure. Patho-
physiological mechanisms underlying ATS-
related CV toxicity involves; increased heart rate,
raised blood pressure, and associated arterial
vasospasm, which are largely attributed to a state
of persistently elevated catecholamine levels.
Long-term use of ATS results in cardiac hypertro-
phy and destruction of the microtubular and actin
structures, which also contributes to the develop-
ment of CV disease in this population [16]. ATS
abuse is considered a potential risk factor for the
development of pulmonary arterial hypertension
[17]. Worse in-hospital outcome has been
observed in khat chewers who were admitted with
acute coronary syndrome as compared to
nonchewers [18]. Khat (Catha edulis) leaves contain
cathinone that is known for its amphetamine-like
effects [19,20].
To our knowledge this is the first study in an
Arab country that addresses CV complications in
the APUDS population. Total UDS of 7450 test
over a period of 8 years is relatively low for a
country that is considered as one of the largest tar-
geted markets in the world. In a single-center
experience of an outpatient setting in the USA
10,011 UDS tests were performed over a 1.5-yearperiod [21]. Overall positivity rate in that study
was 3.6% as compared to 9.6% in our study.
Despite the apparently increasing annual trend
of UDS tests, the positivity rate has been signifi-
cantly decreasing over time, by up to 50% between
2006 and 2013 (p < 0.001; Fig. 4). This observation
might be explained by the increasing awareness
of the medical staff towards substance abuse and
its potential clinical consequences on one hand,
and by the successful governmental security
efforts against drug trafficking and trading on
the other [22].
Out of the 720 positive UDS tests, 42 individuals
(5.8%) were identified to have some sort of CV
complication, which represent 17.4% of the total
admitted APUDS individuals. The remaining
82.6% of APUDS individuals were admitted under
other specialties such as psychiatry, neurosurgery,
general surgery, and internal medicine with
clearly noncardiac conditions. The CV complica-
tions were predominantly due to coronary artery
disease and mostly in form of ACS/MI (n = 31,
74%) out of which ST-elevation MI was present
in 20 cases (48%). Association between ATS use
and ACS/MI has been reported in several studies
and case reports [13,23]. Risk factors for coronary
artery disease in this population included being
male (100%), diabetes mellitus (27.5%), and smok-
ing (at least 60%), which more or less reflect the
usual local population risk factor profile. Individu-
als with CV complications are 1 decade older than
the overall APUDS group (median age, 39 years
and 29 years, respectively), a duration that is long
enough to contribute to coronary artery disease
progression and to expose patients to more ATS-
related CV adverse effects [14]. Nonischemic com-
plications in this study cohort included cardiomy-
opathy (17%), myopericarditis (7%), and
arrhythmia (2%). ATS-related cardiomyopathy is
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direct toxic effect of ATS on myocardium or to
their long-term adverse hemodynamic conse-
quences or both [15,24].
Initial clinical presentation of the study popula-
tion exhibited a wide range of hemodynamic
response and heart rate variation (Table 1). These
hemodynamic variations are probably multifacto-
rial in nature, with the infarct size and location as
well as the degree of left ventricular systolic
dysfunction being probably the most important
determinants. Acute sympathomimetic effects of
ATS use could have been additional contributing
factor in some individuals. The in-hospital mortal-
ity rate in this cohort was 7.2%, despite being
managed in a tertiary care facility and highly spe-
cialized cardiac center that provides primary per-
cutaneous coronary interventions and advanced
critical care support. This finding is very close to
the mortality rate that has been reported in khat
chewers who were admitted with acute coronary
syndrome [18] and in cases of ATS-related
cardiomyopathy [25]. Three patients died before
having a coronary angiogram, four patients left
against medical advice before coronary angiogra-
phy could be performed, and five patients refused
the procedure. This behavior might reflect the
mood instability of such individuals [8,12].
We believe that the rate of ATS-related CV
complications is generally underestimated due to
several reasons including but not limited to:
underreporting of the drug users to the medical
attention; inadequate screening for ATS use and
cardiac complications; missing asymptomatic
individuals or those with subtle CV disease; and
failure to document ATS abuse in the final diagno-
sis. Only one third (33.4%) of the total APUDS
population was admitted to the hospital. Presence
of CV complications in some of those individuals
with APUDS who were discharged could not be
excluded. UDS is a frequently requested emer-
gency room test, particularly for young individu-
als who present with unusual neuropsychiatric
manifestations or unexpected cardiovascular
disease [22]. Requesting UDS test depends on
the physician’s awareness of drug abuse preva-
lence in the community and the degree of clinical
suspicion for drug abuse. Immunoassay is the
most widely used UDS because of its convenience
and cost efficiency [26]. Major limitations of UDS
include its cross-reactivity with a wide range of
commonly prescribed pharmacological agents
giving a high rate of false positive result [27] and
inability to distinguish different substances of
ATS. It is recommended to conduct a confirmatorytest for all APUDS samples using GC-MS, which
is more expensive and time-consuming, but
considered as the gold standard for confirming a
positive result on immunoassay [28]. This confir-
matory test is not readily available for clinical
use in all institutions, including ours. Despite the
potential false positive results, UDS remains
widely used as an evidence of recent drug use,
especially if supported by the appropriate clinical
setting. Despite the limited documentation of his-
tory of drug abuse in the study population, 45% of
cases admitted a history of drug abuse; however,
the duration and pattern of drug abuse were not
specified. Presence of multidrug use has been
reported as almost equivalent to the confirmatory
test in supporting positive UDS test [29]. Opioids,
cannabis, and benzodiazepines were detected at
variable frequencies in the multidrug users.
Our study has the inherent limitations of any
retrospective study. Using an unconfirmed UDS
test as a marker of active ATS use is another lim-
itation, which could not have been avoided due to
lack of the confirmatory test for clinical use in our
institution. Being a single center experience with a
relatively small study population to detect rare
outcomes was an additional limitation.Conclusion
ATS in the form of Captagon tablets are cur-
rently the most frequently abused illicit drugs in
SA. APUDS is frequently encountered in young
Saudi men presenting to the emergency depart-
ment of our institution. Individuals with APUDS
are at increased risk of CV complications and in-
hospital mortality.
A larger, prospective, multicenter study with
regional representation using GC-MS confirmed
APUDS test is strongly recommended. A national
multidisciplinary program for public awareness,
early detection, and continuous monitoring of
ATS abuse in the Saudi community is required
to prevent serious long-term ATS-related adverse
effects including CV complications. Hospital-
based counseling team, with special training in
drug interventions is needed to provide the
appropriate psychological and therapeutic sup-
port for APUDS individuals.Acknowledgments
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